Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Rev Med Chil ; 151(5): 600-609, 2023 May.
Artigo em Espanhol | MEDLINE | ID: mdl-38687542

RESUMO

BACKGROUND: Obesity has been associated with a low-grade proinflammatory state, and it has been related to the development of cancer in general, including hematologic cancer. AIM: The present work aimed to identify the association of the diagnosis of obesity according to the body mass index (BMI) with prognostic factors of adult patients with Acute Lymphoblastic Leukemia (ALL). PATIENTS AND METHOD: This observational, retrospective study included hospitalized patients diagnosed with ALL of the B-cell lineages. BMI was estimated based on the weight and height registered on clinical records at the admission of the patients. The relapse risk and bone marrow relapse were determined, and the survival rate was measured. The statistical analysis included the Kaplan-Meier method using the log-Rank test. RESULTS: This study included 128 clinical records of patients. Weight had no significant association with relapse risk. The frequency of bone marrow relapse was 43.8%. Obesity did not impact overall survival (p = 0.640) or disease-free survival (p = 0.527). The presence of obesity does not behave as a relapse risk variable (p = 0.873). BMI with a 30 kg/m2 cut-off point did not influence relapse risk (OR 1.078). CONCLUSION: Obesity is not an independent risk factor for the prognosis of adult patients with Acute Lymphoblastic Leukemia B-lineage.


Assuntos
Índice de Massa Corporal , Obesidade , Leucemia-Linfoma Linfoblástico de Células Precursoras , Humanos , Masculino , Estudos Retrospectivos , Feminino , Obesidade/complicações , Adulto , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Fatores de Risco , Pessoa de Meia-Idade , Adulto Jovem , Prognóstico , Adolescente , Recidiva , Idoso , Estimativa de Kaplan-Meier , Intervalo Livre de Doença
2.
Nutr Cancer ; 74(1): 82-89, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-33455464

RESUMO

The aim of the study was to determine the prevalence of cancer cachexia according to the clinical stage and determine differences in body composition, usual energy intake, and pro-inflammatory profile between cachectic and non-cachectic patients newly diagnosed with head and neck squamous cell carcinoma (HNSCC). A cross-sectional study was conducted in adult patients diagnosed with HNSCC admitted to the oncology unit before starting cancer treatment. Cancer cachexia was assessed according to Fearon criteria, and patients were divided into two groups: cachectic and non-cachectic patients. Body composition measured by bioelectrical impedance, energy intake, and biochemical and inflammatory markers were assessed. Comparative analyses were performed Student's-T test, using one-way ANOVA, chi-square and Mann Whitney-U test. Of the 79 consecutive patients included in the analysis, 72% (n = 57; 61 ± 15 years) were classified as cachectic and 28% (n = 22;59 ± 10 years) as non-cachectic. According to clinical stage, the prevalence of cachexia was stage I = 8.8%, stage II = 15.8%, stage III = 33.3% and stage IV = 42.1% (P = 0.564) and phase angle showed to be different between these groups (P < 0.05). Body composition showed that fat-free mass and total body water were significantly lower in patients with cachexia (p < 0.05). No differences were observed in phase angle, food intake or inflammatory markers between cachectic and non-cachectic patients. Cancer-cachexia is prevalent in all clinical stages in newly diagnosed patients with HNSCC. Early identification of cancer cachexia will allow initiate specialized nutrition support in a timely manner.


Assuntos
Caquexia , Neoplasias de Cabeça e Pescoço , Caquexia/diagnóstico , Caquexia/epidemiologia , Caquexia/etiologia , Estudos Transversais , Neoplasias de Cabeça e Pescoço/complicações , Humanos , Estudos Prospectivos , Carcinoma de Células Escamosas de Cabeça e Pescoço
3.
Appl Physiol Nutr Metab ; 49(6): 838-843, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38700079

RESUMO

Hospital malnutrition remains a significant public health issue, particularly in developing countries. The Global Leadership Initiative on Malnutrition (GLIM) proposed homogenizing criteria to standardize malnutrition diagnosis. This study aimed to retrospectively determine the prevalence of nutritional risk and malnutrition diagnoses among hospitalized patients using the Nutritional Risk Screening (NRS)-2002 screening instrument and the GLIM criteria, respectively. We conducted a retrospective, cross-sectional study from nutritional records of patients hospitalized in a single centre 2021. Nutrition data from records included medical diagnosis, gender, length of stay, age, weight, height, body mass index, weight loss, calf circumference, and middle upper arm circumference. Nutritional risk and malnutrition were evaluated using NRS-2002 and GLIM criteria. Its concordance was further evaluated by using a Kappa test. The study included 616 records of patients; 52.3% (n = 322) of the population were male. The prevalence of nutritional risk, according to NRS-2002, was 69.5% (n = 428). Nutritional risk as well as malnutrition diagnosis according to GLIM criteria was observed in 87.8% (n = 374) of patienttritional risk and malnutrition were evaluated using NRS-2002 and GLIM criteria. Its concordance was further evaluated by using a Kappa test. Ws. Tools showed a strong concordance (κ= 0.732). All anthropometric data, except for height, were found to be significantly different between patients with moderate and severe malnutrition (p < 0.05). Our findings highlight a high prevalence of malnutrition in this group of hospitalized patients in Mexico. NRS-2002 demonstrated good agreement with the diagnosis of malnutrition according to GLIM criteria and could be considered part of the straightforward two-step approach for malnutrition; however, further studies are needed.


Assuntos
Hospitalização , Desnutrição , Avaliação Nutricional , Estado Nutricional , Humanos , Masculino , Desnutrição/epidemiologia , Desnutrição/diagnóstico , Estudos Transversais , Estudos Retrospectivos , Feminino , Prevalência , Pessoa de Meia-Idade , Idoso , Adulto , Fatores de Risco , Programas de Rastreamento/métodos , Índice de Massa Corporal , Idoso de 80 Anos ou mais
4.
Nutrition ; 128: 112567, 2024 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-39366302

RESUMO

PURPOSE: Malnutrition is frequent in hospitalized patients and is related to functional decline and poorer clinical outcomes. The Patient-Generated Subjective Global Assessment (PG-SGA) is a globally implemented malnutrition tool. We aimed to perform a linguistic and content validation of the translation and cultural adaptation of the PG-SGA for the Spanish language setting. METHODS: This study was conducted in Mexico and Spain. Cancer patients and healthcare professionals (HCPs) of both countries were enrolled. We followed the 10 steps of the International Society for Pharmacoeconomics and Outcomes Research Principles. Patients and HCPs evaluated comprehensibility (Item: I-CI, Scale: S-CI) and difficulty (Item: I-DI, Scale: S-DI) of the Spanish version of the PG-SGA. HCPs also evaluated content validity (i.e., relevance) of the Spanish PG-SGA (Item: I-CVI, Scale: S-CVI). The data were collected by a questionnaire. RESULTS: The study enrolled 84 HCPs and 196 cancer patients from both countries. HCPs rated comprehensibility and difficulty of the professional component as excellent (S-CI = 0.95, S-DI = 0.92), and content validity of the full PG-SGA also as excellent. Patients rated comprehensibility (S-CI) and difficulty (S-DI) of the patient-generated component, that is, the PG-SGA Short Form, as "excellent" (S-CI = 0.98 and S-DI = 0.98). CONCLUSION: Translation and cultural adaptation of the PG-SGA to the Spanish setting according to the International Society for Pharmacoeconomics and Outcomes Research Principles resulted in an instrument perceived as clear and easy to complete by cancer patients and relevant by HCPs to assess the nutritional status.

5.
Nutr Hosp ; 40(6): 1199-1206, 2023 Dec 14.
Artigo em Inglês | MEDLINE | ID: mdl-37929857

RESUMO

Introduction: Introduction: energy metabolism in cancer patients is influenced by different factors. However, the effect of antineoplastic treatment is not clear, especially in women. Objective: to evaluate resting energy expenditure (REE) by indirect calorimetry (IC) before (T0) and after (T1) first cycle period of antineoplastic therapy: radiotherapy (RT), chemotherapy (CT), and concomitant chemoradiation therapy (CRT), quality of life (QoL) and accuracy of REE were compared with international guidelines recommendations per kilogram (European Society for Clinical Nutrition and Metabolism [ESPEN]). Methods: an observational, longitudinal study was conducted in women with gynecological cancer diagnosis undergoing antineoplastic treatment: RT, CT and CRT. Weight loss, actual body weight and height were measured. REE was evaluated in T0-T1 and compared with ESPEN recommendations. Kruskal-Wallis test and Bland-Alman analysis were used to determine the agreement (± 10 % of energy predicted) of REE adjusted by physical activity (TEE) compared with ESPEN recommendations, respectively. Results: fifty-four women with cancer were included: 31.5 % (n = 17) for RT group, 31.5 % (n = 17) for CT group and 37 % (n = 20) for CRT group. REE showed statistical differences between T0 and T1 in the total population (p = 0.018), but these were not associated with anticancer therapy groups (p > 0.05). QoL had no significant changes after treatment (p > 0.05). Accuracy of 25 and 30 kcal/kg compared to TEE was less than 30 %. Conclusion: REE in women with gynecological cancer decreased after antineoplastic treatments but this is not associated with a particular antineoplastic therapy. It is needed to develop research to determine the accuracy of ESPEN recommendations with TEE estimated by IC and clinical factors in women with cancer.


Introducción: Antecedentes: el metabolismo energético en pacientes con cáncer está influenciado por diferentes factores. Sin embargo, el efecto sobre el tratamiento antineoplásico no es claro, especialmente en mujeres. Objetivo: evaluar el gasto energético en reposo (GER) mediante calorimetría indirecta (CI) antes (T0) y después (T1) del primer ciclo del tratamiento antineoplásico: radioterapia (RT), quimioterapia (QT) y quimio-radioterapia concomitante (QRT), calidad de vida (CdV) y precisión del GER con las con las recomendaciones internacionales por kilogramo de peso (European Society for Clinical Nutrition and Metabolism [ESPEN]). Métodos: se realizó un estudio longitudinal, observacional en mujeres con diagnóstico de cáncer ginecológico en tratamiento antineoplásico. Se evaluó el GER en T0 y T1. Se midieron la pérdida de peso, el peso corporal y la talla. Se usaron las pruebas de Kruskal-Wallis y el análisis Bland-Altman para determinar la concordancia (± 10 % de GER) del REE ajustado por actividad física (TEE) en comparación con las recomendaciones de ESPEN. Resultados: se incluyeron 54 mujeres con cáncer; 31,5 % (n = 17) en el grupo RT, 31,5 % (n = 17) en el de QT y 37 % (n = 20) en el de QRT. GER mostró diferencias estadísticas entre T0 y T1 en la población total (p = 0,018); no se asoció con la terapia contra el cáncer (p > 0,05). La calidad de vida no tuvo cambios significativos después del tratamiento (p > 0,05). La precisión de 25 y 30 kcal/kg en comparación con TEE fue inferior al 30 %. Conclusión: el GER en mujeres con cáncer ginecológico disminuyó después del tratamiento antineoplásico, pero no se asoció a una terapia antineoplásica en particular. Es fundamental desarrollar más investigaciones que compare las recomendaciones de ESPEN y con los valores de la CI comparando más factores clínicos para ofrecer una intervención nutricional precisa.


Assuntos
Antineoplásicos , Neoplasias , Humanos , Feminino , Estudos Longitudinais , Estudos Prospectivos , Projetos Piloto , Qualidade de Vida , Metabolismo Basal , Metabolismo Energético , Antineoplásicos/uso terapêutico , Calorimetria Indireta
6.
Rev. méd. Chile ; 151(5): 600-609, mayo 2023. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1560208

RESUMO

ANTECEDENTES: La obesidad se ha asociado con estado proinflamatorio de bajo grado que se ha relacionado con el desarrollo del cáncer en general incluyendo el hematológico. OBJETIVOS: El presente trabajo tiene el objetivo de identificar la asociación del diagnóstico de obesidad acorde al índice de masa corporal (IMC) con indicadores pronóstico de pacientes adultos con Leucemia Linfoblástica Aguda (LAL). PACIENTES Y MÉTODO: Se trata de un estudio observacional, retrospectivo que incluyó pacientes hospitalizados con diagnóstico de LAL de linaje de células B. Se estimó el IMC con base al peso y talla registrado al ingreso de los pacientes. Se determinó el riesgo de recaídas, recaídas a médula ósea y supervivencia. Se utilizó el método de Kaplan-Meier mediante el test log-Rank en el análisis estadístico. RESULTADOS: Se incluyeron 128 pacientes. El peso y el IMC no mostraron una asociación significativa con el riesgo de recaídas. La frecuencia de recaída a médula ósea fue del 43,8%. La obesidad no impactó con la supervivencia global (p = 0,640) ni en la supervivencia libre de enfermedad (p = 0,527). La presencia de obesidad no se comportó como una variable de riesgo de recaída (p = 0,873). El IMC con punto de corte de 30 kg/m2 no se comportó como un factor de riesgo de recaída (OR 1.078). Conclusión: La obesidad no es un factor de riesgo independiente para el pronóstico de los pacientes adultos portadores de Leucemia Linfoblástica Aguda de linaje B.


BACKGROUND: Obesity has been associated with a low-grade proinflammatory state, and it has been related to the development of cancer in general, including hematologic cancer. AIM: The present work aimed to identify the association of the diagnosis of obesity according to the body mass index (BMI) with prognostic factors of adult patients with Acute Lymphoblastic Leukemia (ALL). PATIENTS AND METHOD: This observational, retrospective study included hospitalized patients diagnosed with ALL of the B-cell lineages. BMI was estimated based on the weight and height registered on clinical records at the admission of the patients. The relapse risk and bone marrow relapse were determined, and the survival rate was measured. The statistical analysis included the Kaplan-Meier method using the log-Rank test. Results: This study included 128 clinical records of patients. Weight had no significant association with relapse risk. The frequency of bone marrow relapse was 43.8%. Obesity did not impact overall survival (p = 0.640) or disease-free survival (p = 0.527). The presence of obesity does not behave as a relapse risk variable (p = 0.873). BMI with a 30 kg/m2 cut-off point did not influence relapse risk (OR 1.078). CONCLUSION: Obesity is not an independent risk factor for the prognosis of adult patients with Acute Lymphoblastic Leukemia B-lineage.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Índice de Massa Corporal , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Obesidade/complicações , Prognóstico , Recidiva , Estudos Retrospectivos , Fatores de Risco , Intervalo Livre de Doença , Estimativa de Kaplan-Meier
7.
Nutr Hosp ; 30(1): 173-8, 2014 Jul 01.
Artigo em Espanhol | MEDLINE | ID: mdl-25137277

RESUMO

OBJECTIVE: Hospitalized patients have high risk of malnutrition, specially those with cancer. There are some screening tools that lead to the detection of malnutrition in hospitalized patients, as Nutritional Risk Screening 2002 (NRS-2002), which we used in Mexican population with cancer at the moment of hospital admission to determine the prevalence of malnutrition risk, and to determine as well as the best predictive item to measuring nutritional risk in our population. METHODOLOGY: Nutritional status in cancer patients with NRS 2002 during hospital admission was assessed. To the analysis of variable non statistical parametric tests, student-t test, Pearson and Spearman test, as well as ANOVA test were used. To determine the best item for predicting nutritional risk in Mexican population with cancer, a logistic regression test was applied. RESULTS: Of our population, 50.2% of were classified as patients in nutritional risk at hospital admission. Gender, age, normal levels of IMC lower than 20.5, food intake, weight loss and hematological cancer were associated with nutritional risk (p < 0.05). The best model of logistic regression for predicting nutritional risk were the same used by NRS-2002 questionnaire (p < 0.05). CONCLUSION: Malnutrition prevalence is high in cancer patients and NRS-2002 is a reliable tool for predicting nutritional risk in Mexican population with cancer.


OBJETIVOS: Los pacientes hospitalizados tienen un riesgo alto desnutrición, especialmente aquellos con cáncer. Existen herramientas que evalúan el estado nutricional en pacientes hospitalizados como el Nutritional Risk Screening 2002 (NRS-2002), el cual usamos en el presente trabajo en población mexicana con cáncer durante su hospitalización, para determinar la prevalencia de riesgo de desnutrición y los factores del NRS 2002 que más se asocian al riesgo nutricional. MÉTODOS: Se evaluó el estado nutricional de pacientes con cáncer con el tamizaje NRS-2002, durante su ingreso hospitalario. Se utilizó pruebas estadísticas no paramétricas, la prueba t de student, correlación de Pearson y Spearman, y ANOVA para contrastar las variables que se asocien con riesgo nutricional y por medio de modelos de regresión logística se determinó los ítems del cuestionario de mejor predicción de riesgo de desnutrición en población oncológica mexicana. RESULTADOS: El riesgo nutricional se presentó en el 50,2% de los pacientes durante su ingreso hospitalario. Los factores que más se asocia al riesgo nutricional fueron género, edad, niveles de IMC menores a 20,5, pérdida de peso e ingesta de alimentos y el cáncer hematológico (p < 0,05). El modelo que mejor predijo la presencia de riesgo de desnutrición en nuestra población fueron las mismas variables categorizadas que utiliza la presente encuesta de tamizaje NRS-2002 (p < 0,05). CONCLUSIONES: La prevalencia de desnutrición en el paciente con cáncer es alta y el NRS-2002 es una herramienta confiable en la predicción de riesgo de desnutrición en población oncológica mexicana.


Assuntos
Desnutrição/epidemiologia , Desnutrição/etiologia , Neoplasias/complicações , Idoso , Estudos Transversais , Feminino , Hospitalização , Humanos , Masculino , México , Pessoa de Meia-Idade , Estado Nutricional , Prevalência , Medição de Risco , Fatores de Risco
8.
Asia Pac J Clin Nutr ; 22(3): 426-30, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23945413

RESUMO

Poor nutritional status is a common problem among ovarian cancer patients. In order to detect changes in nutritional status and body composition this study investigates anthropometrical and biochemical parameters among these patients. This study included women with ovarian cancer and woman without cancer. Body composition was assessed by bioelectrical impedance analysis (BIA), anthropometrically, and with DXA scan, and total serum protein, albumin, transferrin, hemoglobin, hematocrit levels and total lymphocyte count was also measured. Data from DXA scan and body composition as assessed by BIA was collected from thirty-one women. Student t-test was used to compare differences in means between groups. This study included 120 women, 57 with ovarian cancer and 63 with benign tumors. Both groups of women were overweight. Body fat by skin-fold thickness, arm circumference, serum albumin, total lymphocytes count, as well as transferrin levels were significantly lower in the ovarian cancer group (p<0.05). Ovarian cancer women had lower fat reserves by skin-fold thickness and lower serum proteins even though they were overweight. However, further studies need to use a body composition assessment on all subjects to confirm these results.


Assuntos
Composição Corporal/fisiologia , Estado Nutricional/fisiologia , Neoplasias Ovarianas/fisiopatologia , Absorciometria de Fóton , Adulto , Antropometria , Proteínas Sanguíneas/análise , Impedância Elétrica , Feminino , Hematócrito , Hemoglobinas/análise , Humanos , Contagem de Linfócitos , Pessoa de Meia-Idade , Albumina Sérica/análise , Dobras Cutâneas , Transferrina/análise
9.
Nutr Hosp ; 33(2): 125, 2016 Mar 25.
Artigo em Espanhol | MEDLINE | ID: mdl-27238806

RESUMO

Introducción y objetivos: la terapia con antioxidantes durante la quimioterapia y radioterapia en pacientes con cáncer cervicouterino es controvertida. Mientras existe evidencia que sugiere que el uso de antioxidantes disminuye los efectos secundarios propios del tratamiento contra el cáncer, hay datos que sugieren que los antioxidantes incrementan el riesgo de recurrencia de cáncer por la afectación de la terapia de los tratamientos. Métodos: se dirigió un estudio clínico controlado en pacientes con cáncer cervicouterino que fueron suplementados con una mezcla de antioxidantes o placebo, con seguimiento por 4 años posteriores al término de su tratamiento antineoplásico para evaluar el efecto de los antioxidantes en la recurrencia. Tomamos datos de niveles de hemoglobina y albúmina. Se analizaron las diferencias entre grupos con la prueba de Chi-cuadrado, la sobrevida se calculó con un análisis multivariado por medio de regresión de COX. Resultados: se dio seguimiento a 103 pacientes con cáncer cervicouterino en etapa clínica IIB y IIIB de los cuales 48% fueron tratados con suplementación de antioxidantes y el 52% con placebo, originalmente y de estos se dio seguimiento a 88 pacientes durante 4 años. El 23,9% de los pacientes tratados presentaron recurrencia por cáncer mientras que el 76,1% no la presentó. El 21,6% de los pacientes presentaron metástasis, el 8% de los pacientes perteneció al grupo de antioxidantes y el 15,9% al grupo placebo (p > 0,05). Implicaciones para los pacientes supervivientes: la suplementación con antioxidantes aparentemente no interfiere con la recurrencia por cáncer, sin embargo no hay evidencia suficiente para probarlo. Posiblemente una dosis distinta sea la clave para un mejor efecto, pero serán necesarios futuros estudios que prueben efectos sobre otro tipo de dosis. Conclusiones: la suplementación con antioxidantes durante el tratamiento de pacientes con cáncer cervicouterino no tiene efectos en la recurrencia por cáncer a 4 años de seguimiento.


Assuntos
Antioxidantes/uso terapêutico , Suplementos Nutricionais , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/terapia , Adulto , Idoso , Antineoplásicos/uso terapêutico , Quimiorradioterapia , Feminino , Hemoglobinas/análise , Hemoglobinas/metabolismo , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologia , Albumina Sérica/análise , Método Simples-Cego , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA